Navigation Links
Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President

LA JOLLA, Calif., Sept. 29, 2011 /PRNewswire/ -- Synthetic Genomics Vaccines, Inc. (SGVI), a privately held company focused on developing next generation vaccines using genomic sequencing and synthetic genomic technologies, announced today that Sammy J. Farah, Ph.D. has been appointed as president.  Dr. Farah brings extensive vaccine expertise and over 15 years of scientific, business and executive management experience in the biotechnology industry to SGVI.

"We are excited to have Sammy join SGVI as he brings not only strong business development and leadership qualities but also a vigorous background in the science behind vaccine development," said J. Craig Venter, Ph.D., Chairman and CEO, SGVI.

Dr. Farah comes to SGVI most recently from Immune Design Corp. where he was chief business officer since 2009. While there he was a leader on the management team responsible for corporate strategy and business development.  He also helped the company complete a Series B funding round and execute a strategic partnership with MedImmune.

Prior to Immune Design Corp., Dr. Farah was at Versant Ventures where he specialized in biotechnology investing and new company formation; and at Merck & Co, Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate new external technology and research opportunities.  

Dr. Farah received his Masters of Business Administration from the Wharton School, University of Pennsylvania, a Ph.D. in Biochemical Engineering from Stanford University and a Bachelor of Science degree in Biochemical Engineering from the Massachusetts Institute of Technology.

"SGVI has access to the most advanced sequencing and synthetic genomic technologies in the world, making it uniquely positioned among the landscape of vaccine companies.  I am delighted to be involved with such an exciting company and committed group of people," said Dr. Farah. "I look forward to applying our resources to develop the next generation of vaccines that will have the greatest positive impact on human health."  

In October 2010, SGVI announced formation along with a three-year collaboration agreement with Novartis to apply synthetic genomics tools and technologies to accelerate the production of the influenza seed strains required for vaccine manufacturing. The agreement, supported by an award from the U.S. Biomedical Advanced Research and Development Authority (BARDA), could ultimately lead to a more timely and effective response to seasonal and pandemic influenza outbreaks.  SGVI also recently completed a funding round that will enable the company to establish operations and support its vaccine programs through initial stages of development.

About Synthetic Genomics Vaccines Inc. (SGVI)

SGVI, a privately held company founded in 2010 by Synthetic Genomics, Inc. and the J. Craig Venter Institute, is dedicated to the development of new vaccines using the advanced tools and technologies of synthetic genomics. The company is headquartered in La Jolla, CA.

SGVI Media Contact:
Heather Kowalski,

SOURCE Synthetic Genomics Vaccines, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R)
2. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
3. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
4. AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
5. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
6. Ethicon, Inc. Expands Hemostasis Product Portfolio with Approval of the Companys First Synthetic Internal Use Sealant
7. Aubrey Inc. Releases New Advanced Biosynthetic Wound Care Product AWBAT Plus
8. Reportlinker Adds Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
9. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
10. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):